作者
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
发表日期
2021/3/1
来源
Annals of the rheumatic diseases
卷号
80
期号
3
页码范围
384-391
出版商
BMJ Publishing Group Ltd
简介
Objectives
The prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases who are frequently treated with disease modifying therapies remains poorly understood. This meta-analysis aims to assess the prevalence and clinical outcomes of COVID-19 in autoimmune diseases.
Methods
Electronic databases were searched for observational and case–controlled studies. We sorted medications into glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologic or targeted synthetic DMARDs (b/tsDMARDs), which was also divided into monotherapy and b/tsDMARDs–csDMARDs combination therapy.
Results
We analysed 62 observational studies with a total of 319 025 patients with autoimmune diseases. The prevalence of COVID-19 was 0.011 (95% CI: 0.005 to 0.025). Meta-analysis of seven case–controlled studies demonstrated that the risk of …
学术搜索中的文章
S Akiyama, S Hamdeh, D Micic, A Sakuraba - Annals of the rheumatic diseases, 2021